Trevi Therapeutics, Inc.

Description

• Trevi Therapeutics, Inc. is a drug development company focused on developing Nalbuphine ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. The Company is pursuing uremic pruritus as the lead indication. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with increased mortality. In September 2015, the Company announced positive results from a Phase 2/3 trial in uremic pruritus, that enrolled 370 patients. Patients receiving 120 mg of Nalbuphine ER (n=120) experienced a 3.5 point reduction in itch intensity from baseline, resulting in a highly statistically significant mean reduction in itch intensity as compared to placebo (p-value=0.017). The Company is also currently conducting a trial in prurigo nodularis, a chronic dermatologic condition characterized by severely pruritic nodules on the skin. There are no approved therapies in the US or Europe for this severe dermatologic condition. The Company expects to report top-line results from this trial in the first half of 2016.Nalbuphine ER is an oral extended release opioid with a unique opioid receptor dual agonist/antagonist mechanism of action, which has been shown in both animal and human clinical studies as being effective in pruritus. Because of Nalbuphine ERs centrally acting dual mechanism of action, the company believes it can have broad utility in treating chronic pruritus and is actively pursuing a second indication in dermatology. Founded in 2011, Trevi is headquartered in New Haven, CT.
• 

  Headquarters:195 Church Street , New Haven, Connecticut, United States

  More
• 

  Phone Number: +1 203-304-2499

• 

  Website: https://www.trevitherapeutics.com

• 

  Employees:25

• 

  Revenue:$1 - 10M

• 

  Legal Name:Trevi Therapeutics, Inc.

• Trevi Therapeutics, Inc.'s Social Media

  
• Is this data correct?

• |  NAICS Code: 325412  |

  Show More